Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus.
Yuming WangXiaofei SuWenli ZhangYunting ZhouXiao ZhouWei YangHui-Qin LiJian-Hua MaPublished in: International journal of endocrinology (2023)
This study suggests that dorzagliatin therapy could effectively improve glycemic control and glucose fluctuation in drug-naïve patients with T2DM.